

Nacho Abia begins tenure as new Grifols CEO

- *Abia will focus on continuing to accelerate the company's growth, furthering its operational excellence and continuing its deleveraging plan*
- *Thomas Glanzmann continues as Executive Chairman, with Abia reporting to him*
- *Raimon Grifols and Víctor Grifols Deu transfer their respective responsibilities to Abia and will remain as advisors in a transition period until May 31, 2024*
- *The moves conclude a meticulously planned corporate governance evolution that began in 2022 to separate ownership from company management*

Barcelona, Spain, April 2, 2024 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announced that on April 1 Nacho Abia officially assumed the role of Chief Executive Officer.

"It's a privilege to help this great company into the next era of sustainable growth, following my predecessors, who have done so much to enhance the health of patients and the well-being of society through essential therapeutics and other healthcare solutions," said Abia. "With sound fundamentals, a talented workforce and exciting innovation, I have no doubt that Grifols has an even greater future ahead."

Abia added that his priorities include accelerating growth, further sharpening operational excellence and continuing to execute the company's deleveraging plan as well as continuing to improve clarity and reduce complexity in operations. Abia reports to Thomas Glanzmann, who remains Executive Chairman.

"With Nacho, Grifols gets the best of both worlds, a veteran healthcare executive whose operational success and personal values will provide familiarity and continuation, yet an outside perspective that will surely enhance critical aspects of how we continue to grow and further improve our company," said Glanzmann.

Effective April 1, Raimon Grifols and Víctor Grifols Deu transferred their respective responsibilities as Chief Corporate Officer and Chief Operating Officer, to Abia. They will serve as advisors in a transition period through May 31, 2024.

"On behalf of the Board, a very special thank you to Raimon and Victor for their valuable service and contributions to Grifols, which have enabled the company to grow successfully and sustainably over the past years," said Glanzmann.

Grifols announced the changes to corporate governance on February 5, 2024. Coinciding with Abia assuming executive functions as CEO on April 1, he also became an executive director of the Grifols Board and is no longer in the category of "other external," held since February 27 of this year.

GRIFOLS

The evolution in corporate governance began in 2022, an initiative of Raimon Grifols and Víctor Grifols Deu, who together with the Board architected a gradual approach to separating the company's ownership from its day-to-day management. As the company's post-pandemic recovery began to gain momentum the Board began to activate the carefully sequenced changes culminating in today's announcement.

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

Spain

Duomo Comunicación

Tel.: +34 91 311 92 89 – +34 91 311 92 90

Raquel Lumbreras (Tel. +34 659 572 185)

Raquel_lumbreras@duomocomunicacion.com

Borja Gómez (Tel. + 34 659 572 185)

Borja_gomez@duomocomunicacion.com

Investors

Investors Relations & Sustainability

inversores@grifols.com - investors@grifols.com

Tel. +34 93 571 02 21

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology, and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership.

GRIFOLS

In 2023, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit [grifols.com](https://www.grifols.com)

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.